<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220522054957N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-08-24</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Combined Herbal Mouthwash (Containing Thymus, Aloe vera, Glycyrrizha and Myrtus ) on Oral Aphthous Lesions</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the Effect of Combined Herbal Mouthwash (Containing Thymus, Aloe vera, Glycyrrizha and Myrtus ) on Oral Aphthous Lesions; A Triple-Blind Randomized Clinical Trial Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-09-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65201</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, a simple randomization method is used with the help of a table of random numbers, Blinding description: The patient, the evaluator (researcher) as well as the data analyst are not aware of the type of mouthwash received by the patient. Mouthwash containers have the same shape and color and are given to patients by another person.</study_design>
      <phase>3</phase>
      <hc_freetext>Oral aphthous lesions.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: This group uses a combined herbal mouthwash containing Thymus, Aloe vera, Glycyrrizha and Myrtus with a concentration of 4%, which was prepared in the Biotechnology Laboratory of Qazvin University of Medical Sciences and formulated in Alborz Darou Company of Qazvin until the aphthous lesion disappears. In this way, 3 times a day (after each meal), 10 ml of mouthwash is used for 1 minute and they avoid eating and drinking for 30 minutes after that. Intervention 2: The second intervention group: This group uses Triamcinolone mouthwash with a concentration of 0.1%, which is made in Alborz Darou Company of Qazvin, until the aphthous lesion disappears. In this way, 3 times a day (after each meal), 10 ml of mouthwash is used for 1 minute and they avoid eating and drinking for 30 minutes after that. Intervention 3: Control group: This group uses placebo mouthwash until the aphthous lesion disappears. In this way, 3 times a day (after each meal), 10 ml of mouthwash is used for 1 minute and they avoid eating and drinking for 30 minutes after that.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Benyamin Kazemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, Shahaamat Alley., Modarres Blvd</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3413815164</zip>
        <telephone>+98 28 3334 4569</telephone>
        <email>benyaminkazemi1999@gmail.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Benyamin Kazemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, Shahaamat Alley., Modarres Blvd</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3413815164</zip>
        <telephone>+98 28 3334 4569</telephone>
        <email>benyaminkazemi1999@gmail.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with Oral aphthous lesions less than 48 hours have passed since the lesion
Oral aphthous lesions are of minor type
The age of patients should be between 18 and 60 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having systemic diseases
Drug use, smoking, alcohol and drug addiction
Patient sensitivity to medicinal plants</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K12.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Recurrent oral aphthae</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: This group uses a combined herbal mouthwash containing Thymus, Aloe vera, Glycyrrizha and Myrtus with a concentration of 4%, which was prepared in the Biotechnology Laboratory of Qazvin University of Medical Sciences and formulated in Alborz Darou Company of Qazvin until the aphthous lesion disappears. In this way, 3 times a day (after each meal), 10 ml of mouthwash is used for 1 minute and they avoid eating and drinking for 30 minutes after that.</i_keyword>
      <i_keyword>The second intervention group: This group uses Triamcinolone mouthwash with a concentration of 0.1%, which is made in Alborz Darou Company of Qazvin, until the aphthous lesion disappears. In this way, 3 times a day (after each meal), 10 ml of mouthwash is used for 1 minute and they avoid eating and drinking for 30 minutes after that.</i_keyword>
      <i_keyword>Control group: This group uses placebo mouthwash until the aphthous lesion disappears. In this way, 3 times a day (after each meal), 10 ml of mouthwash is used for 1 minute and they avoid eating and drinking for 30 minutes after that.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain level of oral aphthous lesions. Timepoint: Measuring the pain level of oral aphthous lesions at the beginning of the study (before the start of the intervention) and 3, 5 and 7 days after the start of using the mouthwash. Method of measurement: By the Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Size of oral aphthous lesions. Timepoint: Measuring the size of oral aphthous lesions at the beginning of the study (before the start of the intervention) and 3, 5 and 7 days after the start of using the mouthwash. Method of measurement: By periodontal probe.</prim_outcome>
      <prim_outcome>Healing duration of oral aphthous lesions. Timepoint: Examining the healing of oral aphthous lesions after starting to use mouthwash, on days 3, 5 and 7 or more, until the day when the lesion is completely healed. Method of measurement: Calendar.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-12</approval_date>
        <contact_name>Ethics committee of Qazvin University of Medical Sciences</contact_name>
        <contact_address>No. 9, Shahaamat Alley., Modarres Blvd Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
